Form 4: BioMarin Pharmaceutical Inc. Director Bienaime Executes Stock Option Plan, Sells Shares

Director Jean Jacques Bienaime of BioMarin Pharmaceutical Inc. exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Jean Jacques Bienaime, a director at BioMarin Pharmaceutical Inc., executed transactions involving the company's common stock.
• On April 11 and 12, 2024, Bienaime exercised stock options to acquire 20,000 shares of common stock on each day at a price of $63.10 per share.
• Concurrently, Bienaime sold 20,000 shares on each day at prices of $90.99 and $91.26, respectively.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan established on August 7, 2023.
• Following these transactions, Bienaime directly owns 474,994 shares of BioMarin common stock.
• Bienaime also indirectly owns 247,333 shares through a family trust and 200 shares held as UTMA custodian for two children.
• After the transactions, Bienaime holds 91,000 stock options from the specific grant.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing plan. There's no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (10b5-1) to avoid accusations of trading on inside information. The market will likely interpret this as a standard part of executive compensation and portfolio management.

Comparison to Industry Standards

• Executive stock option exercises and sales are common in the pharmaceutical industry.
• Companies like Amgen, Gilead, and Vertex regularly see similar filings from their executives.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
• The reported prices are within the typical range for BioMarin's stock, indicating normal market activity.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on shareholders as they are part of a pre-arranged trading plan.
• Employees are unlikely to be affected by these transactions.
• Customers, suppliers, and creditors are not directly impacted by these insider transactions.

Key Dates